Haegarda

Preventing Hereditary Angioedema Attacks

Haegarda is used for the routine prevention of attacks in people with hereditary angioedema (HAE). HAE is a rare genetic disorder caused by a deficiency or malfunction of a protein called C1 esterase inhibitor. This deficiency can lead to sudden, painful, and potentially dangerous swelling in various parts of the body, including the face, hands, feet, digestive tract, and throat.

This medication is intended for long-term use to reduce how often attacks occur and how severe they are when they do happen. It is approved for use in:

• Adults
• Children and adolescents 6 years of age and older

Haegarda is a preventive treatment and is not used to treat an acute HAE attack once it has already begun. Patients should follow their healthcare provider's instructions regarding what to do if an active attack occurs while using this medication.

Restoring Protein Levels

Hereditary angioedema (HAE) is a genetic condition caused by a deficiency or dysfunction of a protein called C1 esterase inhibitor. This protein plays a critical role in regulating the immune system and controlling inflammation.

Preventing Bradykinin Buildup

When C1 esterase inhibitor levels are too low or the protein is not working properly, the body overproduces a substance called bradykinin. Excessive bradykinin causes blood vessels to dilate and leak fluid into the surrounding tissues, leading to the severe swelling attacks seen in HAE.

Haegarda works by:

• Increasing the amount of functional C1 esterase inhibitor in the blood.
• Regulating the chemical pathways that produce bradykinin.
• Preventing the leakage of fluid from blood vessels into tissues.

By maintaining higher levels of this protein through regular injections, Haegarda helps keep the inflammatory system in balance and reduces the frequency of swelling episodes.

Common Side Effects

The most frequently reported side effects of Haegarda include:

• Injection site reactions, such as pain, redness, swelling, itching, or bruising
• Nasopharyngitis (symptoms of a common cold, such as a sore throat or runny nose)
• Dizziness

Serious Side Effects

While less common, some side effects can be severe. Seek medical attention immediately if you experience:

• Allergic reactions: Symptoms may include hives, rash, chest tightness, wheezing, or swelling of the face, lips, or tongue.
• Blood clots: This medication may increase the risk of blood clots. Signs include sudden shortness of breath, chest pain, pain or swelling in an arm or leg, or sudden weakness or numbness, especially on one side of the body.

Because Haegarda is made from human blood, there is a theoretical risk of transmitting infectious agents, though rigorous screening and manufacturing processes are used to minimize this risk.

Hypersensitivity Reactions

Severe allergic reactions, including anaphylaxis, can occur with the use of Haegarda. Symptoms of a serious reaction may include hives, chest tightness, wheezing, or dizziness. If these symptoms occur, immediate medical attention is necessary. This medication is contraindicated in individuals who have had life-threatening hypersensitivity reactions to C1 esterase inhibitor preparations or its components.

Blood Clot Risk

Serious blood clots (thromboembolic events) have been reported with the use of C1 esterase inhibitor products. These events can occur at recommended doses but may be more common with high-dose therapy. Risk factors for blood clots include:

• A history of blood clots or heart disease
• Use of estrogen-containing medications, such as certain birth control or hormone replacement therapies
• The presence of a central venous catheter
• Obesity or prolonged periods of immobility

Monitoring for signs of a blood clot, such as sudden shortness of breath, chest pain, or swelling and redness in an arm or leg, is important for safety.

Risk of Infectious Agents

Because Haegarda is made from human blood (plasma), it may carry a risk of transmitting infectious agents, such as viruses and the agent that causes Creutzfeldt-Jakob disease. The manufacturing process includes screening plasma donors and using specific steps to inactivate or remove viruses to minimize this risk. However, the possibility of transmitting an infection cannot be entirely ruled out.

General Precautions

Haegarda is intended for the prevention of hereditary angioedema (HAE) attacks and is not indicated for the treatment of an acute HAE attack. Patients should be trained on proper subcutaneous injection techniques and how to recognize the signs of serious adverse reactions.

Pregnancy

It is not known whether Haegarda can cause harm to an unborn baby when administered to a pregnant person. Data from clinical trials are currently insufficient to establish a drug-associated risk for major birth defects, miscarriage, or other adverse outcomes.

In animal reproduction studies, no evidence of harm to the fetus was observed when human C1 esterase inhibitor was administered at doses significantly higher than the recommended human dose. However, animal studies do not always predict how a human will respond. Healthcare providers typically recommend using Haegarda during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breastfeeding

It is not known if Haegarda passes into human breast milk, affects milk production, or has any impact on a breastfed infant. Because many drugs are excreted in human milk, caution is advised when using this medication while nursing.

Patients should discuss their treatment plan with a healthcare provider to weigh the benefits of breastfeeding against the clinical need for the medication and any potential effects on the child. Factors to consider include the health benefits of breastfeeding for the infant and the mother's clinical requirement for Haegarda to prevent hereditary angioedema attacks.

Available Forms

Haegarda is supplied as a sterile, lyophilized (freeze-dried) powder in single-use vials. It is intended for subcutaneous administration, which means it is injected into the fatty tissue just under the skin.

The medication is typically provided in a kit that includes the following components:

• A vial containing the freeze-dried protein powder.
• A vial of Sterile Water for Injection, which is used as a diluent to dissolve the powder.

Before administration, the powder must be reconstituted (mixed) with the provided diluent. The resulting solution should be clear and colorless to pale blue. Because the vials are for single use only, any unused portion must be discarded.

FDA Approval and Indications

Haegarda was approved by the U.S. Food and Drug Administration (FDA) in June 2017. It is indicated for routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks. The approval includes use in both adults and pediatric patients 6 years of age and older.

Haegarda is intended for preventive use only. It is not indicated for the treatment of acute HAE attacks once they have already begun.

Regulatory Classification

Haegarda is classified as a C1 esterase inhibitor (human). It is a plasma-derived product, meaning it is manufactured from human blood. As a result, it is subject to specific regulatory requirements for blood products, including rigorous screening and viral inactivation processes to minimize the risk of transmitting infectious agents.

Safety and Monitoring

There are no Boxed Warnings or Risk Evaluation and Mitigation Strategies (REMS) currently required by the FDA for Haegarda. Regulatory labeling includes standard precautions for plasma-derived products regarding the theoretical risk of pathogen transmission. The FDA continues to monitor the safety profile of the medication through post-marketing surveillance.

Insurance and Prior Authorization

Haegarda is a specialty medication, and most insurance plans require prior authorization before they will cover the cost. This process involves your healthcare provider submitting documentation to the insurance company to prove the medical necessity of the drug for preventing hereditary angioedema (HAE) attacks.

Specialty Pharmacy Requirements

Because Haegarda requires specific handling and storage, it is typically dispensed through a specialty pharmacy rather than a standard retail pharmacy. These pharmacies often provide additional support services, such as coordinating delivery and explaining insurance benefits.

Financial Assistance Programs

The manufacturer of Haegarda offers support programs to help reduce the financial burden for patients. These may include:

• Copay Assistance: Eligible patients with commercial insurance may qualify for programs that lower out-of-pocket costs.
• Patient Assistance Programs: For individuals without insurance or those who are underinsured, the manufacturer may provide the medication at a reduced cost or for free based on financial need and eligibility criteria.

The total cost of treatment also depends on the prescribed dose, which is calculated based on the patient's body weight (60 International Units per kilogram of body weight).